Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Marcus Noel"'
Autor:
Scott Daigle, Sunil Sharma, Xinyan Zhang, Martin Gutierrez, Patricia Fraser, David Sommerhalder, Scott Boiko, Esha A Gangolli, Bhaskar Srivastava, Frank G Basile, Marcus Noel, Amanda Hoerres, Nawaid Rana, Rama Balaraman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/eeeb277cba37407485a3b247289a090b
Autor:
Marcus Noel, Kevin Fiscella
Publikováno v:
Health Equity, Vol 3, Iss 1, Pp 532-540 (2019)
Purpose: Pancreatic cancer remains a major health concern; in the next 2 years, it will become the second leading cause of cancer deaths in the United States. Health disparities in the treatment of pancreatic cancer exist across many disciplines, inc
Externí odkaz:
https://doaj.org/article/349f613d85e3479f943e23d750771632
Autor:
Margaret A. Tempero, Uwe Pelzer, Eileen M. O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii-Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus S. Noel, Giovanni Luca Frassineti, Yan-Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni, Richard Epstein, Paul Vasey, Jeremy Shapiro, Matthew Burge, Yu Jo Chua, Marion Harris, Nick Pavlakis, Niall Tebbutt, Gerald Prager, Christian Dittrich, Friedrich Längle, Kathrin Philipp-Abbrederis, Richard Greil, Herbert Stöger, Michael Girschikofsky, Thomas Kuehr, Jean-Luc Van Laethem, Stéphanie Laurent, Neesha Dhani, Yoo Joung Ko, Scot Dowden, Petr Kavan, Mustapha Édouard Tehfe, Eugen Kubala, Milan Kohoutek, Per Pfeiffer, Mette Yilmaz, Vibeke Parner, Tapio Salminen, Leena-Maija Soveri, Eija Korkeila, Pia Osterlund, Julien Taieb, David Tougeron, Pascal Artru, François Xavier Caroli-Bosc, Rosine Guimbaud, Antony Turpin, Thomas Walter, Jean Baptiste Bachet, Volker Kunzmann, Florian Kreth, Andreas Block, Marino Venerito, Helmut Oettle, Meinolf Karthaus, Jörg Trojan, Gunnar Folprecht, Markus Lerch, Frank Kullmann, Marcel Reiser, Volker Heinemann, Marcus-Alexander Wörns, Holger Schulz, Benjamin Garlipp, Thomas Yau, Lam Stephen Chan, Balazs Juhasz, László Landherr, Tamas Pinter, György Bodoky, Zsuzsanna Kahán, Raymond McDermott, Derek Power, Luca Gianni, Salvatore Siena, Michele Milella, Alfredo Falcone, Rossana Berardi, Cinzia Bagalà, Francesco Di Costanzo, Fausto Roila, Andrea Ardizzoni, Evaristo Maiello, Silvia Fanello, Johanna Wilmink, Jan Willem de Groot, Geert Creemers, Eduardo Barroso, Tânia Rodrigues, Cristina Sarmento, Cheng Ean Chee, David Tai, Teresa Macarulla Mercade, Manuel Hidalgo Medina, Alfredo Carrato Mena, Joan Maurel Santasusana, Maria Jose Flor Oncala, Carlos Gomez Martin, Rafael Lopez, Andres Muñoz, Ruth Vera Garcia, Inmaculada Ales, Berta Laquente Sáez, Fernando Rivera, Javier Sastre, Cheng-Chung Wu, Yu-Wen Tien, De-Chuan Chan, Tsann-Long Hwang, Jeffry Evans, Jonathan Wadsley, Pippa Corrie, Andrew Biankin, Andrew Ko, Dana Cardin, Elena Chiorean, Johanna Bendell, Anne Noonan, Hedy Kindler, Nishan Fernando, Muhammad Beg, Thomas George, Marcus Noel, Noelle LoConte, Francis Arena, James Posey, Rajat Malhotra, Charles Lopez, Davendra Sohal, Robert McWilliams, Warren Brenner, Mark Womack, Rahul Seth, Renuka lyer, Nathan Bahary, Robert Marsh, Robert Ramirez, Cynthia Chua, James Reeves, Gulam Manji, Anthony El-Khoueiry, Robert Weaver, Vaibhav Sahai, Wells Messersmith, Robert Dreicer, Ahmed Zakari, Andrea Bullock, Benjamin Musher, Mitesh Borad, Edward Kim, David Bajor, Tim Huyck, Hassan Hatoum, Henry Xiong, Boris Pasche, Jill Lacy, Olugbenga Olowokure, Allen Cohn, Donald Richards, Robert Martin, Andrew Paulson, Paul Fanta, Smitha Krishnamurthi, Paul Oberstein, Jyotsna Fuloria
Publikováno v:
Scientia
PURPOSE This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430 ). METHODS We assi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::192d001f322850ad486a84bac981c740
https://lirias.kuleuven.be/handle/20.500.12942/715374
https://lirias.kuleuven.be/handle/20.500.12942/715374
Autor:
Keith T. Flaherty, Alice P. Chen, Peter J. O'Dwyer, Lyndsay N. Harris, Carlos L. Arteaga, Barbara A. Conley, Stanly R. Hamilton, P. Mickey Williams, David Patton, Larry V. Rubinstein, Lisa M. McShane, Shuli Li, Robert J. Gray, Helen X. Chen, John J. Wright, Edith P. Mitchell, Gregory J. Riely, Marcus Noel, Fengmin Zhao, Douglas B. Johnson
Supplementary Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::062bb0c8d61e0546bf2732428d41259a
https://doi.org/10.1158/1078-0432.22479149.v1
https://doi.org/10.1158/1078-0432.22479149.v1
Autor:
Keith T. Flaherty, Alice P. Chen, Peter J. O'Dwyer, Lyndsay N. Harris, Carlos L. Arteaga, Barbara A. Conley, Stanly R. Hamilton, P. Mickey Williams, David Patton, Larry V. Rubinstein, Lisa M. McShane, Shuli Li, Robert J. Gray, Helen X. Chen, John J. Wright, Edith P. Mitchell, Gregory J. Riely, Marcus Noel, Fengmin Zhao, Douglas B. Johnson
Purpose:Substantial preclinical evidence and case reports suggest that MEK inhibition is an active approach in tumors with BRAF mutations outside the V600 locus, and in BRAF fusions. Thus, Subprotocol R of the NCI-MATCH study tested the MEK inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b796d15815b569437fbea2208d7d43d
https://doi.org/10.1158/1078-0432.c.6530147.v1
https://doi.org/10.1158/1078-0432.c.6530147.v1
Autor:
Keith T. Flaherty, Alice P. Chen, Peter J. O'Dwyer, Lyndsay N. Harris, Carlos L. Arteaga, Barbara A. Conley, Stanly R. Hamilton, P. Mickey Williams, David Patton, Larry V. Rubinstein, Lisa M. McShane, Shuli Li, Robert J. Gray, Helen X. Chen, John J. Wright, Edith P. Mitchell, Gregory J. Riely, Marcus Noel, Fengmin Zhao, Douglas B. Johnson
Supplementary Figure 2: "Swimmer's plot as in Figure 2B also demonstrating mutation locations in individual patients, showing treatment duration for all 32 evaluable patients and their occurrence of response (*), disease progression (+) and death (#)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::292de4135adf90aacfb557cbec4c0147
https://doi.org/10.1158/1078-0432.22479155.v1
https://doi.org/10.1158/1078-0432.22479155.v1
Autor:
Keith T. Flaherty, Alice P. Chen, Peter J. O'Dwyer, Lyndsay N. Harris, Carlos L. Arteaga, Barbara A. Conley, Stanly R. Hamilton, P. Mickey Williams, David Patton, Larry V. Rubinstein, Lisa M. McShane, Shuli Li, Robert J. Gray, Helen X. Chen, John J. Wright, Edith P. Mitchell, Gregory J. Riely, Marcus Noel, Fengmin Zhao, Douglas B. Johnson
1) Eligible mutations/fusions, 2) identified mutations/fusions, 3) Treatment-related toxicities, 4) Number of treatment cycles and reasons for discontinuation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcacf39c1bc2f7091e6b7d369736080e
https://doi.org/10.1158/1078-0432.22479146.v1
https://doi.org/10.1158/1078-0432.22479146.v1
Autor:
Ruth Plummer, Mikael Sodergren, Brid Ryan, Ilian Tachkov, Vikash Reebye, Tim Meyer, David Pinato, Debashis Sarker, Bristi Basu, Sarah Blagden, Natalie Cook, Jeff Evans, Jeffrey Yachnin, Cheng-Ean Chee, Daneng Li, Anthony El-Khoueiry, Maria Diab, Kai-Wen Huang, Antonio D'Alessio, Claudia Fulgenzi, Marcus Noel, Bridget Keenan, Devalingam Mahalingam, Nina Raulf, Rose Hogson, Choon Ping Tan, Joanna Nicholls, Alison Adderkin, Julia Vassiliadou, Robert Habib, John Rossi, Nagy Habib
Publikováno v:
Regular and Young Investigator Award Abstracts.
Publikováno v:
Hematology/oncology clinics of North America. 36(5)
Advanced pancreatic cancer remains one of the deadliest malignancies in 2022. Although there has been significant progress in treatment options with improved outcomes in many cancers, this growth has been slow in pancreatic cancer. This article exami